U.S. Markets open in 5 hrs 10 mins
  • S&P Futures

    4,267.00
    -9.75 (-0.23%)
     
  • Dow Futures

    33,898.00
    -65.00 (-0.19%)
     
  • Nasdaq Futures

    13,454.75
    -38.50 (-0.29%)
     
  • Russell 2000 Futures

    1,986.30
    -2.80 (-0.14%)
     
  • Crude Oil

    88.36
    +0.25 (+0.28%)
     
  • Gold

    1,778.40
    +1.70 (+0.10%)
     
  • Silver

    19.64
    -0.10 (-0.49%)
     
  • EUR/USD

    1.0174
    -0.0006 (-0.0610%)
     
  • 10-Yr Bond

    2.8930
    0.0000 (0.00%)
     
  • Vix

    20.40
    +0.71 (+3.61%)
     
  • GBP/USD

    1.2041
    -0.0010 (-0.0867%)
     
  • USD/JPY

    135.1720
    +0.0820 (+0.0607%)
     
  • BTC-USD

    23,421.39
    -414.66 (-1.74%)
     
  • CMC Crypto 200

    557.04
    -15.78 (-2.75%)
     
  • FTSE 100

    7,503.75
    -12.00 (-0.16%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

AMYRIS CLOSES ACQUISITION OF MENOLABS

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EMERYVILLE, Calif., March 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that it has closed the acquisition of the assets of MenoLabs, LLC, a company founded by women to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause.

Amyris Logo (PRNewsfoto/Amyris, Inc.)
Amyris Logo (PRNewsfoto/Amyris, Inc.)

MenoLabs, a growing women's wellness brand, is focused on addressing perimenopause and menopause symptoms and offers research-backed, all-natural treatments for menopause symptoms. Over the past two years, MenoLabs has developed and launched eight products, including its lead product, MenoFit, an all-natural menopause relief supplement. MenoLabs generates a subscription-based, recurring revenue stream through its online sales, in addition to the Subscribe & Save option offered via the Amazon channel. The company is further expanding through retail channels in 2022. Additionally, MenoLabs offers MenoLife, a highly rated perimenopause and menopause health tracker app which helps users track and analyze more than 40 menopause-related symptoms.

About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

About MenoLabs
MenoLabs was founded to fundamentally change how menopause is addressed. The brand's mission is to provide options to treat menopause symptoms, drive research for women's health and change how society approaches, views and educates around the topic of menopause. MenoLabs has developed a line of all natural, proprietary supplements focused on treating perimenopause and menopause symptoms, in addition to MenoLife, a leading menopause health tracker app that provides women a voice and community. MenoLife also provides symptom tracking to further fuel research and advancements in women's health.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-closes-acquisition-of-menolabs-301500717.html

SOURCE Amyris, Inc.